1. Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance
- Author
-
Emmanuel Chamorey, Jean-Louis Formento, C. Onesto, Ramaioli A, Gilles Pagès, Hannoun-Lévi Jm, Institut de signalisation, biologie du développement et cancer (ISBDC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Dept of Radiation Oncology, Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA)-UNICANCER-Université Côte d'Azur (UCA), Dept. of Statistics, and Dept of Oncopharmacology
- Subjects
Male ,Vascular Endothelial Growth Factor A ,Cancer Research ,Pathology ,Cellular differentiation ,medicine.medical_treatment ,Cell ,MESH: Laryngeal Neoplasms ,MESH: Aged, 80 and over ,0302 clinical medicine ,MESH: RNA, Small Interfering ,Tumor Cells, Cultured ,RNA, Small Interfering ,vascular endothelial growth factor-A ,MESH: Aged ,Aged, 80 and over ,0303 health sciences ,MESH: Middle Aged ,RNA-Binding Proteins ,Cell Differentiation ,Middle Aged ,Prognosis ,Poly(A) binding protein-interacting protein 2 ,head and neck carcinoma ,3. Good health ,Survival Rate ,Vascular endothelial growth factor A ,Cytokine ,medicine.anatomical_structure ,Oncology ,MESH: Repressor Proteins ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Female ,MESH: Cell Differentiation ,Adult ,medicine.medical_specialty ,MESH: Survival Rate ,Blotting, Western ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,MESH: Prognosis ,03 medical and health sciences ,medicine ,MESH: Blotting, Northern ,MESH: Blotting, Western ,Humans ,prognostic value ,MESH: Tumor Cells, Cultured ,Laryngeal Neoplasms ,Molecular Diagnostics ,Survival rate ,Aged ,Retrospective Studies ,030304 developmental biology ,MESH: Humans ,MESH: Vascular Endothelial Growth Factor A ,Growth factor ,Head and neck cancer ,MESH: Adult ,MESH: Retrospective Studies ,[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,Blotting, Northern ,medicine.disease ,human tumour specimens ,Head and neck squamous-cell carcinoma ,MESH: Male ,MESH: Head and Neck Neoplasms ,Repressor Proteins ,MESH: RNA-Binding Proteins ,Cancer research ,MESH: Female - Abstract
International audience; Vascular endothelial growth factor-A (VEGF-A) has been demonstrated to play an important role in tumour angiogenesis and to influence prognosis in many cancers. However its prognostic value in head and neck squamous cell carcinomas (HNSCCs) remains controversial. Therefore, we investigated the clinical relevance of VEGF-A expression in HNSCCs and analysed whether its expression was associated with PAIP2 protein levels, a VEGF-A mRNA-binding partner that strongly regulates VEGF-A expression in tissue culture. We determined the correlation of VEGF-A and PAIP2 protein levels, quantitatively evaluated in tumour tissue homogenates from 54 patients with HNSCC, to clinicopathological parameters. We showed that VEGF-A expression in HNSCC is correlated to the stage of tumour differentiation (P=0.050) and is an independent prognostic factor for progression-free survival (P=0.001) and overall survival (P=0.0004). In a pharynx carcinoma cell line, we demonstrated by RNA interference that VEGF-A expression is closely controlled by PAIP2. Moreover, in human HNSCCs, VEGF-A expression is significantly correlated to PAIP2 protein levels (P=0.0018). Nevertheless, PAIP2 expression is associated with neither clinicopathological factors nor patient's survival. Our data suggest that, in contrast to PAIP2 protein levels, which are unrelated to tumour prognosis, VEGF-A expression could serve as a prognostic marker in head and neck cancer and may be helpful for targeted therapies.
- Published
- 2006